COMPLETE LEARNING NOTE: ANTIFUNGAL PHARMACOLOGY

From Absolute Beginner to MBBS Examination Mastery

---

---

SECTION 1: BIG PICTURE OVERVIEW

What Problem Do Antifungal Drugs Solve?

What exactly is a fungus?

Why are fungi so hard to kill?

• Bacteria are prokaryotes - simple cells with no nucleus, with a cell wall made of peptidoglycan.
• Fungi are eukaryotes - complex cells with a nucleus, with a cell wall made of chitin, and a cell membrane containing ergosterol.

• Drugs that kill bacteria do NOT kill fungi (fungi have no peptidoglycan, so penicillin does nothing to them).
• Drugs that kill fungi have a much higher risk of also harming human cells (because fungi and human cells share similar basic machinery).

The One Key Difference That Antifungals Exploit

---

---

SECTION 2: BUILD THE FOUNDATION

2A. Normal Fungal Biology (What Fungi Look Like)

• Round, single-celled organisms.
• They reproduce by budding (one cell pinches off a smaller copy of itself).
• Example: Candida albicans, Cryptococcus neoformans

    Parent yeast cell
         O
        /
       o  ← bud forming (daughter cell)

• Long, branching filaments called hyphae (singular: hypha).
• A mass of hyphae is called a mycelium.
• These are the fuzzy structures you see on old bread.
• Example: Aspergillus fumigatus, Rhizopus (Mucor)

    ===========================  ← hypha (long filament)
         |         |
    =====         =====          ← branching

• These fungi exist as molds in the environment (at room temperature, ~25°C) but transform into yeasts in the human body (at body temperature, ~37°C).
• "Dimorphic" = two forms ("di" = two, "morphic" = shape)
• This is important clinically because these cause endemic mycoses (infections in specific geographic regions).
• Examples: Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Sporothrix schenckii
• Memory trick: "HCBS" - Histoplasma, Coccidioides, Blastomyces, Sporothrix (all dimorphic, all systemic/endemic)

---

2B. The Fungal Cell - A Structural Tour

    OUTSIDE ENVIRONMENT
           |
    ████████████████████   ← CELL WALL (chitin + beta-1,3-D-glucan)
    ████████████████████   [Target of: Echinocandins → inhibit glucan synthesis]
    ████████████████████
           |
    ════════════════════   ← CELL MEMBRANE (contains ERGOSTEROL)
    ════════════════════   [Target of: Polyenes → bind ergosterol, punch holes]
    ════════════════════   [Target of: Azoles → block ergosterol SYNTHESIS]
                           [Target of: Allylamines → block ergosterol SYNTHESIS (earlier step)]
           |
    ......................   ← CYTOPLASM
    ......................   [Target of: Flucytosine → disrupts DNA/RNA synthesis]
    ......................   [Target of: Griseofulvin → disrupts spindle (for dermatophytes only)]
           |
    ██████████████████████  ← NUCLEUS (contains DNA)

• Multiple drug classes attack ergosterol (polyenes, azoles, allylamines, morpholines) - they just attack it at different points.
• This is why ergosterol is the "holy grail" target of antifungal therapy.

---

2C. Fungal Pathophysiology - When Fungi Attack

• HIV/AIDS patients (especially with CD4 count below 200)
• Patients on chemotherapy for cancer (neutropenic patients)
• Solid organ transplant recipients (on immunosuppressive drugs)
• Patients on prolonged high-dose corticosteroids
• Very premature newborns
• Patients with hematological malignancies (leukemia, lymphoma)
• Patients on broad-spectrum antibiotics for a long time (these kill normal bacteria and allow fungi to overgrow - this is called "superinfection")
• Diabetic patients (especially for mucormycosis)

---

2D. The Drug Intervention Points - Where Drugs Can Act

ERGOSTEROL BIOSYNTHESIS PATHWAY:
(This is the fungal cholesterol factory)

Acetyl-CoA
    ↓
Squalene
    ↓ ← [ALLYLAMINES and BENZYLAMINES block HERE - inhibit squalene epoxidase]
Squalene epoxide
    ↓
Lanosterol
    ↓ ← [AZOLES block HERE - inhibit 14α-demethylase / CYP51]
Fecosterol / other intermediates
    ↓
ERGOSTEROL → goes into cell membrane
    ↑
    [POLYENES bind directly to finished ergosterol in the membrane → punch holes]

CELL WALL SYNTHESIS:
UDP-glucose → β-1,3-D-glucan (main cell wall component)
    ↑
    [ECHINOCANDINS block β-1,3-D-glucan synthase → weak, crumbling cell wall]

NUCLEIC ACID SYNTHESIS:
5-FC (flucytosine) enters cell → converted to 5-FU → blocks DNA/RNA synthesis
    ↑
    [FLUCYTOSINE disrupts the cell's information system]

---

---

SECTION 3: DRUG CLASS FRAMEWORK

---

CLASS 1: POLYENES

What are they?

---

Mechanism of Action

1. Amphotericin B is administered and reaches the fungal cell membrane.
2. It recognizes and binds to ergosterol in the fungal membrane.
3. Multiple Amphotericin B molecules cluster together and insert into the membrane, forming ring-shaped channels (like punching holes in a water balloon).
4. These channels (pores) allow essential ions - especially potassium (K+) - to leak out of the fungal cell.
5. The fungal cell loses its internal balance of salts and water → it cannot function → it dies.

• Human membranes contain cholesterol, not ergosterol.
• Amphotericin B has a much higher affinity for ergosterol than cholesterol.
• But its affinity for cholesterol is NOT zero.
• At therapeutic doses, some binding to kidney tubule cell membranes occurs → nephrotoxicity (kidney damage).

---

Spectrum of Activity

• Candida species (most)
• Cryptococcus neoformans
• Aspergillus species
• Mucorales (Rhizopus, Mucor, Lichtheimia) - Amphotericin B is the ONLY drug effective here
• Histoplasma, Blastomyces, Coccidioides
• Fusarium

---

Amphotericin B Formulations

• The liposomes preferentially deliver the drug to sites of infection (where fungal membranes are present).
• Less free drug reaches kidney tubule cells → less kidney damage.
• Lipid formulations are 3-5 times less nephrotoxic than conventional Amphotericin B.

---

Pharmacokinetics of Amphotericin B

---

Adverse Effects

• Occurs in virtually EVERY patient on prolonged therapy.
• Mechanism: Amphotericin B damages kidney tubule cells directly (by binding to cholesterol in their membranes) and also causes renal vasoconstriction (blood vessel narrowing in the kidney, reducing blood flow).
• Results in: Decreased GFR, elevated serum creatinine, renal tubular acidosis, hypokalemia (low potassium), hypomagnesemia (low magnesium).
• Remember: You must check electrolytes (especially K+ and Mg2+) and kidney function regularly.
• Solution: Use lipid formulations; ensure adequate hydration; give IV saline before each dose.

• Occurs 1-3 hours after starting the infusion.
• Fever, rigors (shaking chills), headache, nausea, vomiting, hypotension, dyspnea.
• Mechanism: Amphotericin B triggers release of cytokines (inflammatory chemicals) like IL-1 and TNF from immune cells.
• Solution: Premedicate with paracetamol, diphenhydramine (antihistamine), and hydrocortisone. Slow the infusion rate.

• Mechanism: Amphotericin B suppresses erythropoietin (EPO) production by the kidney.
• EPO is the hormone that stimulates red blood cell production.
• Less EPO → fewer red blood cells → normochromic normocytic anemia.

• Kidney tubule damage leads to wasting of potassium and magnesium in the urine.
• Clinically important: Hypokalemia can cause dangerous heart arrhythmias.
• Must be replaced with oral/IV supplementation.

---

Clinical Uses of Amphotericin B

---

Nystatin

• Same mechanism as Amphotericin B (binds ergosterol, forms pores).
• Too toxic for systemic use - causes severe GI side effects.
• Used only topically for:
  • Oral candidiasis (thrush) - oral suspension or lozenges ("swish and swallow")
  • Vaginal candidiasis - pessaries
  • Cutaneous candidiasis - cream/powder
• Brand name: "Mycostatin"

---

---

CLASS 2: AZOLE ANTIFUNGALS

What are they?

• Imidazoles - contain 2 nitrogens in the ring (older generation, mostly topical)
• Triazoles - contain 3 nitrogens in the ring (newer generation, systemic and topical)

---

Mechanism of Action

1. Azoles enter the fungal cell.
2. They inhibit the enzyme 14α-demethylase (also called CYP51 - a fungal cytochrome P450 enzyme).
3. This enzyme is responsible for converting lanosterol → ergosterol.
4. Without this step, the cell cannot make ergosterol.
5. Two problems result:
   • Ergosterol depletion - the membrane becomes structurally weak and leaky.
   • Accumulation of toxic sterol intermediates (like lanosterol and methylated sterols) - these intermediates are toxic to the fungal cell.
6. Membrane function is disrupted → cell growth stops.

• How strongly they bind to the enzyme (potency)
• Which fungi they cover (spectrum)
• Their pharmacokinetics (absorption, distribution, metabolism)
• Their side effects

• Human cells also have cytochrome P450 enzymes, but the fungal CYP51 has a slightly different structure.
• Azoles have higher affinity for the fungal enzyme than for human CYP450.
• However, they do NOT perfectly avoid human CYP450 - this is why drug interactions are a major concern.

---

Azole Drug Interactions - CRITICAL

---

Individual Azoles - Detailed

FLUCONAZOLE

• Excellent oral bioavailability (~90%) - oral and IV forms are interchangeable.
• Distributes into virtually all body fluids including CSF (unique among azoles - excellent CNS penetration).
• Excreted unchanged in urine - dose must be reduced in renal failure.
• Long half-life (~30 hours) - once-daily dosing.

• Vulvovaginal candidiasis - single oral dose of 150 mg is enough!
• Oropharyngeal and esophageal candidiasis (oral thrush)
• Candidemia in non-critically ill, non-immunosuppressed patients
• Cryptococcal meningitis - consolidation and maintenance therapy (after initial Amphotericin B induction)
• Prophylaxis in immunocompromised patients (transplant, HIV)
• Coccidioidal meningitis - drug of choice here
• NOT for Aspergillus infections

• Generally well-tolerated.
• Nausea, headache, elevated liver enzymes.
• Reversible alopecia (hair loss) with prolonged high-dose use.
• QT prolongation (rare).
• IMPORTANT: Even low doses during pregnancy → miscarriage, stillbirth, and cardiac defects in the baby. Contraindicated in pregnancy.
• High doses (>800mg/day) → significantly more hepatotoxicity.

---

ITRACONAZOLE

• Available as capsule (absorption requires acidic stomach - take WITH food; impaired by H2 blockers or PPIs), oral solution in cyclodextrin (absorption better on empty stomach), and IV solution.
• Poor CSF penetration - NOT suitable for CNS infections.
• Metabolized by CYP3A4 in the liver → many drug interactions.
• Highly protein-bound; distributes well into skin, nails, lung.
• Steady state only reached after 13-15 days.

• Histoplasmosis (mild-moderate disease)
• Blastomycosis
• Sporotrichosis (cutaneous form)
• Onychomycosis (nail infections) - oral form
• Aspergillosis (second-line)
• Tinea capitis (with oral formulation)

• Negative inotropic effect (decreases heart muscle contraction) → contraindicated in heart failure
• Hepatotoxicity
• Hypertension
• Peripheral neuropathy
• Drug interactions (CYP3A4 inhibitor)

---

VORICONAZOLE

• Available as oral tablets, IV solution, and eye drops.
• Shows nonlinear pharmacokinetics in adults (saturation of metabolism at higher doses means blood levels can spike unexpectedly).
• Metabolized by CYP2C19 and CYP3A4.
• Genetic polymorphism in CYP2C19 is clinically important: "poor metabolizers" (common in East Asian populations) have up to 4x higher blood levels → more toxicity. Therapeutic drug monitoring (TDM) is recommended.
• Penetrates CSF.
• Does NOT need dose adjustment for renal failure.

• Invasive aspergillosis - FIRST-LINE (drug of choice) - superior to Amphotericin B (success rate ~52% vs ~32%)
• Fusariosis (second-line)
• Serious Candida infections (when resistant to fluconazole)
• Chronic pulmonary aspergillosis

• Visual disturbances - most characteristic. Transient, reversible blurring, photophobia, altered color perception, hallucinations. Occurs in ~30% of patients. Mechanism: effect on retinal ion channels. Usually resolves within 30 minutes.
• Photosensitivity - skin becomes very sensitive to sunlight → can cause exaggerated sunburn, and with long-term use, squamous cell carcinoma and melanoma of skin (serious concern).
• Hallucinations, encephalopathy, seizures (especially with high blood levels).
• Hepatotoxicity.
• QT prolongation.
• Periostitis (bone pain, periosteal new bone formation) - with prolonged use; can mimic cancer metastases on bone scan.
• Fluorosis - elevated fluoride levels (voriconazole contains fluorine atoms).

---

POSACONAZOLE

---

ISAVUCONAZOLE

---

KETOCONAZOLE (historical but still tested)

• Inhibits CYP enzymes responsible for steroid hormone synthesis in humans.
• Results in: Gynecomastia (breast enlargement in men), decreased libido, impotence, menstrual irregularities.
• Inhibits cortisol synthesis → adrenal insufficiency.
• This has led to an interesting clinical use: Ketoconazole is sometimes used to reduce cortisol levels in Cushing's syndrome when surgery is not possible.

---

---

CLASS 3: ECHINOCANDINS

What are they?

---

Mechanism of Action

1. Echinocandins are administered intravenously.
2. They reach the fungal cell and bind to the enzyme β-1,3-D-glucan synthase (the machine that builds the fungal cell wall).
3. Glucan synthase normally adds glucose units together to form β-1,3-D-glucan - the main structural component of the fungal cell wall.
4. With glucan synthase inhibited, the fungal cell can no longer build or repair its cell wall.
5. The cell wall becomes weak and defective.
6. The fungal cell bursts due to osmotic pressure (like a balloon with a hole in it).

• Human cells have NO cell wall at all.
• Therefore, glucan synthase does not exist in human cells.
• There is no human target for these drugs to accidentally hit.
• This makes echinocandins among the safest antifungal drugs.

---

Properties of Echinocandins

• Fungicidal against Candida (kill the fungus outright).
• Fungistatic against Aspergillus (inhibit hyphal growth at the tips).
• NOT effective against Cryptococcus (it has very little glucan in its wall), Mucor, Fusarium, or the endemic dimorphic fungi.
• Only available as intravenous formulations (they are large molecules and are not absorbed orally).
• All require once-daily IV dosing.
• Generally well-tolerated.

---

Individual Echinocandins

---

Clinical Uses of Echinocandins

• Candidemia and invasive candidiasis - FIRST-LINE (drug of choice)
• Step-down therapy: start with echinocandin IV → switch to fluconazole oral once patient is stable and organism is confirmed susceptible
• Prophylaxis of Candida infections in hematopoietic stem cell transplant (micafungin)
• Esophageal candidiasis
• Second-line therapy for invasive aspergillosis (when voriconazole fails or is not tolerated)

---

Adverse Effects of Echinocandins

• Fever, rash, nausea
• Phlebitis (vein inflammation) at the injection site
• Histamine-like reaction (flushing) if infused too rapidly → always infuse slowly
• Elevated liver enzymes
• Caspofungin: avoid with cyclosporine (high rate of liver enzyme elevation)

---

---

CLASS 4: ANTIMETABOLITE - FLUCYTOSINE (5-FC)

What is it?

---

Mechanism of Action

1. 5-FC enters the fungal cell through a specific transporter called cytosine permease (this transporter is present in fungi but NOT in mammalian cells - an important selectivity mechanism).
2. Inside the fungal cell, the enzyme cytosine deaminase converts 5-FC → 5-fluorouracil (5-FU).
3. 5-FU is then converted to:
   • 5-fluorodeoxyuridine monophosphate (5-FdUMP) → inhibits thymidylate synthase → blocks DNA synthesis
   • 5-fluorouridine triphosphate (FUTP) → incorporates into fungal RNA → disrupts protein synthesis
4. Both DNA and protein synthesis in the fungus are disrupted → fungal cell death.

• Human cells do NOT have cytosine deaminase in significant amounts.
• Therefore, 5-FC cannot be converted to 5-FU inside human cells... much. However, intestinal bacteria can convert some 5-FC to 5-FU, which is then absorbed - this accounts for some GI and bone marrow toxicity.

• Amphotericin B punches holes in the fungal membrane.
• This makes the membrane more permeable - more 5-FC enters the fungal cell.
• The combination is much more effective than either drug alone.
• The classic combination is Amphotericin B + Flucytosine for Cryptococcal meningitis induction therapy.

---

Spectrum of Activity

• Active against Candida and Cryptococcus neoformans primarily.
• Used in combination with Amphotericin B for systemic candidiasis and cryptococcal meningitis.
• Also active against some Chromoblastomycosis agents (combined with itraconazole).
• Fungistatic.

---

Resistance

• Decreased activity or loss of cytosine permease (drug cannot enter cell).
• Decreased or absent cytosine deaminase (drug cannot be converted to active form).
• Decreased activity of enzymes that phosphorylate 5-FU.

---

Pharmacokinetics

• Well absorbed orally.
• Excellent CSF penetration - very important for cryptococcal meningitis.
• Excreted unchanged in urine - dose must be reduced in renal failure.
• Monitoring of serum levels (target: 25-100 μg/mL) is recommended.

---

Adverse Effects

• Bone marrow suppression (most important): Neutropenia (low white blood cells), thrombocytopenia (low platelets). This is due to 5-FU generated by intestinal bacteria being absorbed.
• Nausea, vomiting, diarrhea, and severe enterocolitis.
• Hepatotoxicity - elevated liver enzymes.
• Monitoring: Complete blood count (CBC) and liver function tests (LFTs) regularly.

---

---

CLASS 5: ALLYLAMINES AND BENZYLAMINES (Squalene Epoxidase Inhibitors)

What are they?

1. Ergosterol depletion - membrane becomes leaky.
2. Toxic accumulation of squalene - squalene builds up and kills the cell directly.

• Terbinafine (allylamine) - oral and topical
• Naftifine (allylamine) - topical only
• Butenafine (benzylamine) - topical only

---

Terbinafine - The Important Drug in This Class

• Onychomycosis (nail fungal infection) - drug of CHOICE. More effective than itraconazole and griseofulvin. Treatment duration: 6 weeks (fingernails), 12 weeks (toenails).
• Tinea capitis (scalp ringworm) - oral therapy
• Tinea pedis, tinea corporis, tinea cruris - topical (1 week usually enough)
• Tinea versicolor (caused by Malassezia furfur)

• Oral bioavailability only ~40% (first-pass metabolism).
• Highly lipophilic → deposits into skin, nails, and fat tissue.
• Very long terminal half-life (200-400 hours) because it slowly releases from tissues - this is beneficial for nail infections (drug stays in nail even after stopping).
• Metabolized by multiple CYP enzymes; inhibits CYP2D6.
• Contraindicated in moderate-severe hepatic or renal impairment.

• GI disturbances (nausea, diarrhea)
• Hepatotoxicity (monitor LFTs)
• Taste disturbances - taste may be altered or lost (dysgeusia/ageusia) - often reversible
• Skin rash
• Rare but serious: Stevens-Johnson syndrome; bone marrow suppression; drug-induced lupus

---

---

CLASS 6: GRISEOFULVIN (Special Mechanism)

What is it?

---

Mechanism of Action

1. Griseofulvin is absorbed from the GI tract and concentrates in keratin-containing tissues (skin, hair, nails).
2. It enters dividing fungal cells.
3. It binds to tubulin, preventing tubulin polymerization (assembly of the spindle fibers).
4. Without a functional spindle, the cell cannot divide.
5. Additionally, it causes abnormal spindle formation → produces multinucleated, giant cells that cannot function.

• Griseofulvin has very high affinity for keratin - the protein that makes skin, hair, and nails.
• This means it accumulates exactly where dermatophyte infections live.

---

Spectrum

---

Clinical Uses

• Tinea capitis - oral griseofulvin remains a commonly used option, especially in children.
• Tinea corporis, tinea pedis, tinea cruris - when terbinafine/itraconazole not available.
• Onychomycosis - still used but requires very long treatment (6-12 months for toenails).

---

Pharmacokinetics

• Take with fatty food - griseofulvin is highly fat-soluble; fatty meals double its absorption.
• Ultramicrosize formulation has better absorption than microsize.
• Metabolized in liver (CYP3A4).

---

Adverse Effects

• Headache (very common, often dose-related)
• Nausea, vomiting, diarrhea
• Photosensitivity (skin becomes sensitive to light)
• Hepatotoxicity - contraindicated in liver disease
• Neurological: Confusion, dizziness, peripheral neuropathy
• Teratogenic - absolute contraindication in pregnancy
• Lupus-like syndrome
• Disulfiram-like reaction with alcohol (flushing, palpitations, nausea when alcohol is consumed)

• Induces hepatic CYP enzymes → reduces levels of warfarin, oral contraceptives (OCP failure - increased pregnancy risk), cyclosporine.
• Rifampicin reduces griseofulvin levels.
• Classic exam fact: Griseofulvin reduces the effectiveness of oral contraceptives.

---

---

SECTION 4: TEACH USING ANALOGIES

The Master Analogy Framework for Antifungals

POLYENES (Amphotericin B): "The Sniper at the City Gates"

---

AZOLES: "Cutting Off the City's Steel Factory"

---

ECHINOCANDINS: "The Bricklayer's Tools are Stolen"

---

FLUCYTOSINE: "The Trojan Horse with a Fake Blueprint"

---

ALLYLAMINES (Terbinafine): "Poisoning the Steel Factory's Ore Supply"

---

GRISEOFULVIN: "Gluing the Train Tracks"

---

---

SECTION 5: STEP-BY-STEP CLINICAL REASONING

Case 1: Patient with Candidemia

• Post-transplant immunosuppression (tacrolimus suppresses T-cells, prednisone suppresses all immune cells).
• Hospital exposure + invasive lines + antibiotics → all risk factors for Candida.

• First-line for candidemia = Echinocandin (caspofungin, micafungin, or anidulafungin).
• Why? Fungicidal, safe, low drug interactions (mostly), reliable activity against most Candida species.
• NOT fluconazole initially because:
  • Candida species needs to be confirmed as azole-susceptible first.
  • C. glabrata and C. krusei may be azole-resistant.
  • In critically ill or immunocompromised patients, empirical echinocandin preferred.

• Once blood cultures clear AND the Candida species is confirmed as fluconazole-susceptible AND the patient is clinically stable → step-down to oral fluconazole is appropriate and cost-effective.

• Fluconazole inhibits CYP3A4 → increases tacrolimus levels significantly.
• Need to REDUCE tacrolimus dose and MONITOR tacrolimus blood levels carefully.
• Echinocandins have fewer CYP interactions - safer in this context initially.

• At least 2 weeks after last positive blood culture and resolution of symptoms.

---

Case 2: Invasive Aspergillosis in a Neutropenic Patient

• A ground-glass opacity surrounding a denser nodule on CT.
• Represents hemorrhage around a fungal nodule.
• Highly suggestive of angioinvasive Aspergillus infection.

• Aspergillus fumigatus (most common).
• Neutropenic patients cannot clear Aspergillus spores inhaled from environment.

• Voriconazole - first-line for invasive aspergillosis.
• Harrison's 2025: "Voriconazole is superior to amphotericin B for the treatment of invasive aspergillosis, in which it increases the likelihood of a successful outcome from about 30% to about 50%."

• WRONG choice - fluconazole has NO activity against molds like Aspergillus. Common exam trap.

• At least 6-12 weeks, and until immune reconstitution (neutrophil recovery).

---

Case 3: Cryptococcal Meningitis in HIV Patient

• Cryptococcus neoformans - a yeast with a large polysaccharide capsule.
• India ink stain: highlights the capsule (appears as clear halo around dark yeast cells).

1. Induction (2 weeks): Liposomal Amphotericin B + Flucytosine - the gold standard combination. Amphotericin B punches holes in the membrane, allowing more flucytosine to enter (synergy).
2. Consolidation (8 weeks): Fluconazole 400 mg/day - fluconazole penetrates CSF well.
3. Maintenance (at least 1 year): Fluconazole 200 mg/day - until CD4 count recovers above 200 with antiretrovirals.

• Voriconazole has poor activity against Cryptococcus. Fluconazole is better for Cryptococcus.
• Echinocandins are NOT effective (Cryptococcus has very little cell wall glucan).

---

Case 4: Tinea Capitis in a Child

• Usually Trichophyton tonsurans (in most countries) or Microsporum canis.

• The fungus has invaded the hair shaft.
• Topical drugs cannot penetrate deep enough.
• Oral therapy is mandatory for tinea capitis.

• Options: Griseofulvin (traditional, first-line for children in many guidelines), Terbinafine (superior efficacy, shorter duration), or Itraconazole.
• Griseofulvin: 8-12 weeks; must take with fatty food.
• Terbinafine: 4-6 weeks; superior against Trichophyton.

• Selenium sulfide or ketoconazole shampoo (topical) to reduce spore shedding and prevent spread to contacts - used alongside oral therapy, not as standalone.

---

---

SECTION 6: MEMORY TOOLS

Master Mnemonic: Drug Classes and Their Targets

• Ergosterol binders - Polyenes (Amphotericin B, Nystatin)
• Azoles - Ergosterol synthesis inhibitors (14α-demethylase inhibitors)
• Glucan wall bashers - Echinocandins
• Lie (pretend to be a building block) - Flucytosine (antimetabolite)
• Early block - Allylamines/Griseofulvin (squalene epoxidase / microtubules)

---

Mnemonic: Triazoles - "Five Very Incredible Pharmacology Professors"

• Fluconazole
• Voriconazole
• Itraconazole
• Posaconazole
• (Isa)vuconazole

---

Mnemonic: Echinocandins - "CMA" (or "Caspofungin Micafungin Anidulafungin")

• Caspofungin
• Micafungin (the only one needing NO loading dose)
• Anidulafungin

---

Mnemonic: Dimorphic Fungi - "HBCS" = "Histology Books Can Stump"

• Histoplasma capsulatum
• Blastomyces dermatitidis
• Coccidioides immitis
• Sporothrix schenckii

---

Mnemonic: Adverse Effects of Amphotericin B - "FRANK"

• Fever and chills (infusion reaction)
• Renal damage (nephrotoxicity - most serious)
• Anemia (suppresses EPO)
• Nausea, vomiting
• Kalium loss (hypokalemia - K = kalium in Latin)

---

Mnemonic: Azole Drug Interactions - "WARP CQ"

• Warfarin (bleeding)
• Anticonvulsants (phenytoin - bidirectional)
• Rifampicin (decreases azole levels - rifampicin is an INDUCER)
• Pimozide/QT drugs (arrhythmia)
• Cyclosporine/tacrolimus (nephrotoxicity)
• Quinidine (arrhythmia)

---

Mnemonic: Voriconazole Unique Side Effects - "VHL-P"

• Visual disturbances (most characteristic - colored/blurred vision)
• Hallucinations
• Light sensitivity (photosensitivity → skin cancer with prolonged use)
• Periostitis (bone pain)

---

Master Comparison Table: Antifungal Drug Classes

---

Drug of Choice Summary Table

---

---

SECTION 7: EXAMINER'S CORNER

Most Tested Facts

1. Drug of choice for Invasive Aspergillosis = Voriconazole (not Amphotericin B, not fluconazole)
2. Drug of choice for Mucormycosis = Amphotericin B (only effective drug; azoles do NOT work)
3. Echinocandins are first-line for candidemia - not fluconazole empirically
4. Fluconazole = best CSF penetration among azoles
5. Amphotericin B = broadest spectrum antifungal
6. Nephrotoxicity of AmB = most serious adverse effect
7. Liposomal formulations = less nephrotoxic than conventional deoxycholate
8. Flucytosine = NEVER used alone (rapid resistance)
9. Flucytosine + AmB = synergistic for Cryptococcal meningitis
10. Griseofulvin = take with fatty food + oral contraceptive interaction
11. Terbinafine = drug of choice for onychomycosis
12. Voriconazole's unique side effect = visual disturbances (colored vision, hallucinations)
13. Ketoconazole = endocrine side effects (gynecomastia, adrenal suppression)
14. Itraconazole = contraindicated in heart failure (negative inotrope)
15. Echinocandins = only IV; no oral formulation (classic MCQ)

---

Essay Questions (Most Likely)

1. "Classify antifungal drugs. Describe the mechanism of action of azoles. Add a note on drug interactions of azoles." [15 marks]
2. "Describe the pharmacology of Amphotericin B with special emphasis on its adverse effects and how they can be minimized." [10 marks]
3. "Write a short note on echinocandins." [5 marks]
4. "Describe the mechanism of action and therapeutic uses of triazole antifungals." [10 marks]
5. "Compare and contrast the pharmacology of Amphotericin B, Fluconazole, and Caspofungin." [10 marks]
6. "Describe antifungal drug resistance mechanisms." [5 marks]
7. "A patient with AIDS develops cryptococcal meningitis. How would you treat this patient? Discuss the pharmacology of the drugs used." [10 marks]

---

Short Notes (Most Likely)

1. Amphotericin B (mechanism + adverse effects)
2. Echinocandins
3. Fluconazole
4. Voriconazole
5. Drug of choice in fungal infections (table)
6. Antifungal resistance mechanisms
7. Flucytosine
8. Terbinafine
9. Lipid formulations of Amphotericin B
10. Ketoconazole endocrine effects

---

Viva Questions

1. "What is the mechanism of action of Amphotericin B?"
   • Expected answer: Binds ergosterol in fungal membrane → forms transmembrane channels → leakage of K+ and other ions → cell death.
2. "Why is Amphotericin B nephrotoxic?"
   • Cross-reactivity with cholesterol in kidney tubule cell membranes + renal vasoconstriction.
3. "What is the drug of choice for invasive aspergillosis? Why not fluconazole?"
   • Voriconazole. Fluconazole has NO activity against molds; it only covers yeasts.
4. "What is ergosterol and why is it important in antifungal pharmacology?"
   • Fungal equivalent of cholesterol; main structural component of fungal cell membrane; target for multiple drug classes.
5. "Why are echinocandins considered the safest antifungals?"
   • Target β-1,3-D-glucan synthase, an enzyme that does not exist in human cells → no direct mammalian target.
6. "What are the adverse effects of azoles? Explain their basis."
   • Drug interactions via CYP450 inhibition; teratogenicity; QT prolongation; hepatotoxicity; ketoconazole-specific endocrine effects.
7. "Why is flucytosine always combined with another antifungal?"
   • Rapid resistance develops when used alone; combination prevents resistance emergence and has synergistic effects.
8. "What is the unique adverse effect of voriconazole?"
   • Visual disturbances (transient altered/colored vision, photophobia); also photosensitivity leading to skin cancer; and hallucinations.
9. "What is the mechanism of antifungal resistance to azoles?"
   • Upregulation of drug efflux pumps (MDR1/CDR transporters); mutation/overexpression of 14α-demethylase (ERG11 gene); alteration of biofilm formation (in Candida).
10. "A patient on warfarin is started on fluconazole. What do you expect?"
    • Fluconazole inhibits CYP2C9 (warfarin metabolism) → warfarin levels rise → INR increases → bleeding risk. Warfarin dose must be reduced and INR monitored.

---

Classic Exam Traps (Do NOT Fall Into These)

1. Trap: Choosing fluconazole for Aspergillus or Mucor.
   • Reality: Fluconazole only covers YEASTS. Zero activity against molds.
2. Trap: Using flucytosine alone.
   • Reality: Never use flucytosine as monotherapy. Resistance emerges within days.
3. Trap: Thinking echinocandins cover Cryptococcus.
   • Reality: Cryptococcus has very little glucan in its wall. Echinocandins are essentially useless against Cryptococcus.
4. Trap: Saying AmB can be taken orally for systemic infections.
   • Reality: AmB is not absorbed from the GI tract. Must be IV for systemic infections.
5. Trap: Saying all lipid formulations of AmB have different efficacy.
   • Reality: All lipid formulations have similar efficacy to conventional AmB but are LESS TOXIC.
6. Trap: Voriconazole is safe in renal failure.
   • Reality: Oral/tablet voriconazole is fine in renal failure (no dose adjustment needed). BUT the IV formulation is dissolved in sulfobutyl ether beta-cyclodextrin, which accumulates in renal failure → use ORAL form in moderate-severe renal failure.
7. Trap: Itraconazole is the drug of choice for Aspergillus.
   • Reality: Voriconazole replaced itraconazole as first-line for invasive aspergillosis.
8. Trap: Topical antifungals work for tinea capitis.
   • Reality: Tinea capitis ALWAYS requires ORAL therapy. Topical alone is ineffective.
9. Trap: Fluconazole is safe in pregnancy.
   • Reality: All azoles are potentially teratogenic. Even low-dose fluconazole in early pregnancy is linked to miscarriage, stillbirth, and cardiac defects.
10. Trap: Thinking micafungin needs a loading dose.
    • Reality: Micafungin is the only echinocandin that does NOT need a loading dose.

---

---

SECTION 8: ANTIFUNGAL RESISTANCE - A DEDICATED SECTION

Why Does Resistance Matter?

---

Mechanisms of Azole Resistance

1. Efflux pump upregulation (most common in Candida)
   • Normal fungi have transporter proteins (ABC transporters: CDR1, CDR2; MFS transporter: MDR1) that pump drugs out of the cell.
   • In resistant strains, these pumps are overexpressed → drug is pumped out faster than it can inhibit the enzyme.
   • Analogy: You try to fill a bathtub but someone turned on all the drains.
2. Target mutation (ERG11 gene mutations)
   • The gene encoding 14α-demethylase (ERG11) mutates.
   • The enzyme's structure changes slightly → azole can no longer bind effectively.
   • Common in azole-resistant C. albicans and C. auris.
3. Target overexpression (ERG11 overexpression)
   • More enzyme is produced than the drug can inhibit.
   • Like hiring 10x more workers to replace the ones the saboteur inactivated.
4. Biofilm formation
   • Candida can form thick biofilms on catheters, prosthetic valves, etc.
   • Biofilms are 1000x more resistant to antifungals than free-floating cells.
   • Mechanism: Reduced drug penetration into biofilm; altered gene expression in biofilm cells; presence of "persister" cells.
   • Solution: Remove the infected device if possible.
5. Agricultural azole use and Aspergillus resistance
   • Azole fungicides (tebuconazole, propiconazole) are heavily used in agriculture on crops.
   • Aspergillus fumigatus in the environment is exposed to these fungicides → develops azole resistance → patients inhale already-resistant Aspergillus.
   • This is a major concern in the Netherlands and other agricultural countries.

---

Mechanisms of Echinocandin Resistance

• Mutations in FKS1 and FKS2 genes (which encode glucan synthase).
• These mutations change the shape of the enzyme so echinocandins cannot bind.
• Emerging clinical problem in C. glabrata especially.

---

Mechanisms of Amphotericin B Resistance (Rare)

• Changes in the ergosterol content of the membrane (reduced ergosterol → drug has less to bind).
• Mutations in ergosterol biosynthesis genes (ERG genes) resulting in altered sterols that AmB binds poorly.
• Very rare clinically - this is why AmB resistance development is uncommon and AmB remains valuable.

---

---

SECTION 9: HIGH-YIELD REVISION SHEET

ONE-PAGE RAPID REVIEW

1. Ergosterol in membrane → Polyenes (AmB, Nystatin)
2. Ergosterol synthesis (14α-demethylase) → Azoles
3. Glucan cell wall synthesis → Echinocandins
4. DNA/RNA synthesis → Flucytosine
5. Squalene epoxidase → Allylamines (Terbinafine)

---

---

---

• Fluconazole = best CSF penetration (Cryptococcus, Coccidioides meningitis)
• Echinocandins = NOT absorbed orally; IV only
• Echinocandins = NOT effective for Cryptococcus or Mucor
• Flucytosine = NEVER monotherapy
• AmB lipid formulations = same efficacy, less nephrotoxicity
• Voriconazole IV = AVOID in renal failure (cyclodextrin vehicle accumulates)
• Itraconazole capsule = take WITH food; solution = take WITHOUT food
• Griseofulvin = take WITH fatty food; inhibits OCPs

---

1. Aspergillosis → Voriconazole
2. Mucormycosis → AmB (only drug!)
3. Candidemia → Echinocandin (first-line)
4. Cryptococcal meningitis → AmB + 5-FC
5. AmB toxicity → Nephrotoxicity
6. Voriconazole toxicity → Visual disturbances
7. Ketoconazole toxicity → Gynecomastia
8. Griseofulvin → OCP failure
9. Flucytosine → Bone marrow suppression (never alone)
10. Echinocandins = safest (target not in human cells)

---

---

SECTION 10: SELF-ASSESSMENT

---

---

---

---

---

1. Prevents the emergence of resistant mutants
2. Is synergistic (AmB opens membrane pores → more 5-FC enters) Using 5-FC alone virtually guarantees treatment failure.

---

---

• Gynecomastia (breast enlargement in men) - due to reduced testosterone synthesis
• Decreased libido, impotence
• Menstrual irregularities in women
• Adrenal insufficiency - due to reduced cortisol synthesis This is also why ketoconazole is sometimes used off-label to control cortisol hypersecretion in Cushing's syndrome.

---

---

1. Upregulation of efflux pumps (CDR1, CDR2 - ABC transporters; MDR1 - MFS transporter) - pumps fluconazole out of the cell faster than it can inhibit the enzyme.
2. Mutations in ERG11 (the gene encoding 14α-demethylase) - the enzyme's structure changes so fluconazole cannot bind effectively.
3. Overexpression of ERG11 - more enzyme is produced, overwhelming the drug's inhibitory capacity.
4. Biofilm formation - reduces drug penetration significantly.

---

---

---

QUICK REFERENCE: KEY MECHANISMS DIAGRAM

                    FUNGAL CELL WALL
                  [chitin + β-1,3-D-glucan]
                    ↑
    ECHINOCANDINS block β-1,3-glucan synthase
    (Caspofungin, Micafungin, Anidulafungin)


                    FUNGAL CELL MEMBRANE
                  [ergosterol-containing]
                    ↑
    POLYENES bind ergosterol → punch holes → K+ leaks out → cell death
    (Amphotericin B, Nystatin)


              ERGOSTEROL BIOSYNTHESIS PATHWAY
    Squalene ──[SQUALENE EPOXIDASE]──→ Squalene epoxide
                    ↑
    ALLYLAMINES block here (Terbinafine, Naftifine)
    (Squalene accumulates → toxic)

    Squalene epoxide → Lanosterol
    Lanosterol ──[14α-DEMETHYLASE]──→ Ergosterol
                    ↑
    AZOLES block here (Fluconazole, Voriconazole, etc.)
    (Ergosterol depletes + toxic sterols accumulate)


                    FUNGAL NUCLEUS/DNA
                    ↑
    FLUCYTOSINE enters cell → converted to 5-FU
    → inhibits DNA synthesis (thymidylate synthase)
    + disrupts RNA


                    FUNGAL SPINDLE (during cell division)
                    ↑
    GRISEOFULVIN binds tubulin → prevents spindle assembly
    → cell division blocked
    (Only for dermatophytes)

---

• Lippincott Illustrated Reviews: Pharmacology, 8th Edition
• Harrison's Principles of Internal Medicine, 22nd Edition (2025)
• Goldman-Cecil Medicine, International Edition
• Goodman & Gilman's Pharmacological Basis of Therapeutics, 13th Edition
• Sherris & Ryan's Medical Microbiology, 8th Edition
• Medical Microbiology, 9th Edition

---

What This Note Contains